

Human PD-L1 inhibitor V TFA

Cat. No.:	HY-P2478A	
Molecular Formula:	C ₆₇ H ₁₀₄₅ F ₃ N ₂₀ O ₂₀ S	
Molecular Weight:	1599.73	
Sequence Shortening:	LDYVNRKMYQ	LDYVNRKMYQ (TFA salt)
Target:	PD-1/PD-L1	
Pathway:	Immunology/Inflammation	
Storage:	Sealed storage, away from moisture	
	Powder -80°C 2 years	
	-20°C 1 year	
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 100 mg/mL (62.51 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	Preparing Stock Solutions		1 mg	5 mg	10 mg
		1 mM	0.6251 mL	3.1255 mL	6.2511 mL
5 mM		0.1250 mL	0.6251 mL	1.2502 mL	
	10 mM	0.0625 mL	0.3126 mL	0.6251 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: PBS Solubility: 100 mg/mL (62.51 mM); Clear solution; Need ultrasonic				

BIOLOGICAL ACTIVITY

Description	Human PD-L1 inhibitor V TFA, a human PD-1 protein binding peptide with a K _d value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1 ^[1] .
In Vitro	Human PD-L1 inhibitor V (Ar5M_2) is a peptide designed with anchor residues Y56, R113, A121, D122 and Y123 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Qiao Li, et al. Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. *Oncotarget*. 2016 Oct 4;7(40):64967-64976.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA